Community Trust ScoreVerified
Windtree Therapeutics, a Pennsylvania-based biotech company that made headlines in July for adopting a Binance Coin (BNB) treasury strategy, suffered a massive 77% stock price collapse on Wednesday. The plunge came after the company disclosed that the Nasdaq Stock Market had issued a delisting notice, citing failure to comply with the exchange’s listing standards.
The sharp decline marks one of the steepest single-day drops for a Nasdaq-listed biotech this year and underscores the risks facing smaller firms experimenting with crypto-treasury strategies.
Nasdaq Moves To Suspend Trading
In a filing with the U.S. Securities and Exchange Commission (SEC) on Tuesday, Windtree (trading under ticker WINT) confirmed it had received a noncompliance notice from Nasdaq. The notice cited Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum closing bid price of at least $1.00 per share.
Windtree’s shares have consistently traded below that threshold since mid-July, with Wednesday’s collapse pushing them down another 77.2% to $0.11 per share. According to Google Finance data, shares dropped further by another 4.7% in after-hours trading.
Nasdaq will officially suspend Windtree’s trading on Thursday. While delisting does not dissolve a company, it severely limits its access to capital markets and investor visibility, often forcing affected firms to trade over-the-counter (OTC).
The BNB Treasury Bet
Windtree Therapeutics had briefly captured investor attention last month when it revealed a BNB treasury strategy. On July 16, the firm disclosed a $60 million purchase agreement with Build and Build Corp, with options to expand the deal by an additional $140 million.
The move was part of a growing trend among smaller public companies to add exposure to cryptocurrencies in their balance sheet. By adopting a BNB-centric treasury model, Windtree positioned itself as one of the first biotech firms to leverage crypto reserves as a financial hedge.
Initially, the reveal gave WINT shares a short-lived boost, climbing 32% in two days. However, optimism quickly faded. By late July, the company’s stock had plunged more than 90% from its local peak, with investors increasingly skeptical of whether the BNB strategy could offset Windtree’s core operational challenges in the biotech sector.
Additional Financing Deals Raise Questions
In late July, Windtree followed up with further reveals , including a $500 million equity line of credit with an unnamed institutional investor, alongside a $20 million stock-purchase agreement with Build and Build Corp to expand its BNB holdings.
However, since then, the company has remained quiet. It has not disclosed the size of its BNB reserves, nor whether it intends to continue building its crypto-treasury strategy after the delisting news.
The lack of transparency has added to market doubts, particularly as other firms with similar strategies have either been forced to abandon them or struggled to maintain compliance with major exchanges.
CEO Vows Continued Disclosures
Despite the Nasdaq suspension, Windtree’s CEO, Jed Latkin, confirmed that the company would continue meeting its SEC reporting obligations.
“We remain committed to transparency with our shareholders and will continue to provide disclosures as required by regulators,” Latkin said in the filing.
While some firms, such as Argo Blockchain, have managed to regain compliance and re-list after temporary Nasdaq suspensions, Windtree’s path to recovery remains uncertain. The firm faces not only financial headwinds but also reputational challenges after the steep collapse in its share price.
Biotech Meets Crypto: A Risky Experiment
Windtree’s experiment with a BNB treasury reflects a broader wave of publicly listed companies exploring digital assets as part of their balance-sheet management. The trend was popularized by high-profile Bitcoin treasury strategies, most notably by MicroStrategy.
However, smaller firms in sectors outside of tech or finance have found it much harder to replicate those results. While a well-timed crypto allocation can generate short-term investor buzz, sustaining long-term confidence requires transparency, operational strength, and adherence to compliance standards.
For Windtree, which was already struggling to maintain Nasdaq listing requirements, the BNB treasury may have created more volatility than stability.
BNB Soars Despite Windtree’s Woes
Interestingly, the delisting news did not dampen BNB’s own performance. On Wednesday, BNB surged 5.6% to $876.26, setting a new all-time high. It was one of the top-performing blue-chip altcoins as the broader crypto market rebounded from a two-week correction.
This divergence highlights the growing gap between companies leveraging crypto as a treasury asset and the underlying tokens themselves. While BNB continues to thrive amid increased adoption, Windtree’s troubles suggest that poorly executed treasury strategies can backfire, especially for firms already on shaky financial footing.
What’s Next for Windtree?
With its Nasdaq listing set to be suspended, Windtree now faces the prospect of trading OTC, where liquidity is lower and investor scrutiny is higher. The company has yet to clarify whether it will appeal Nasdaq’s decision or attempt to regain compliance in the future.
Much also depends on whether Windtree can reassure shareholders about its financial position, its biotech pipeline, and its commitment to transparency regarding its BNB treasury.
